


Express Mail Label No.: EV058075492US
Date of Deposit: April 18, 2002



Attorney Docket No. 21402-225 (Cura 525)

3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Gangolli, et al.
SERIAL NUMBER : 10/029,020 EXAMINER : Not Yet Assigned
FILING DATE : December 19, 2001 ART UNIT : 1646
FOR : Polypeptides and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of cited references C1-C28; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21402-225 (Cura 525). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

for  37, 833
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: April 18, 2002



30623

PATENT TRADEMARK OFFICE

RECEIVED
APR 23 2002
TECH CENTER 1600/2900


1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Gangolli, et al.
SERIAL NUMBER: 10/029,020 EXAMINER: Not Yet Assigned
FILING DATE: December 19, 2001 ART UNIT: 1646
FOR: Polypeptides and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents
Washington, D.C. 20231



RECEIVED
APR 23 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Gangolli, et al.
U.S.S.N.: 10/029,020

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-225 (Cura-525).

Respectfully submitted,

for  37,833
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: April 18, 2002

TRA 1657165v1

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/029,020
	Filing Date	12/19/01
	First Named Inventor	Gangolli
	Group Art Unit	1646
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	21402-225 (Cura-525)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	GenBank Accession Number: AAG25939 (07-DEC-2000)
	C2	GenBank Accession Number: AB025413 (08-MAY-1999)
	C3	GenBank Accession Number: AC018997 (05-SEP-2000)
	C4	GenBank Accession Number: AC025535 (07-JUL-2000)
	C5	GenBank Accession Number: AF192499 (13-JAN-2000)
	C6	GenBank Accession Number: AF269232 (29-MAY-2000)
	C7	GenBank Accession Number: AF329193 (10-APR-2001)
	C8	GenBank Accession Number: AF329838 (12-MAR-2001)
	C9	GenBank Accession Number: AJ400878 (06-FEB-2002)
	C10	GenBank Accession Number: AK001872 (22-FEB-2000)
	C11	GenBank Accession Number: AL137432 (18-FEB-2000)
	C12	GenBank Accession Number: AX050019 (12-JAN-2001)
	C13	GenBank Accession Number: L31349 (24-MAR-2000)
	C14	GenBank Accession Number: M55531 (08-NOV-1994)
	C15	GenBank Accession Number: P22732 (01-MAR-2002)
	C16	GenBank Accession Number: P25098 (16-OCT-2001)
	C17	GenBank Accession Number: Q15848 (16-OCT-2001)
	C18	GenBank Accession Number: Q62413 (16-OCT-2001)
	C19	GenBank Accession Number: U58332 (08-MAY-1997)
	C20	GenBank Accession Number: X61157 (23-MAR-1993)
	C21	Post, et al. (1999). "Beta-adrenergic receptors and receptor signaling in heart failure." <i>Annu Rev Pharmacol Toxicol</i> 39: 343-60.

RECEIVED
APR 23 2002
TECH CENTER 160200